Merck & Co., Inc.
NYSE:MRKDrug Manufacturers - General
-$1.32 today
- Market cap
- $339.66B
- Beta
- 0.22
- P/E (TTM)
- 31.6
- EPS (TTM)
- $3.61
- Dividend yield
- 2.94%
Volume 9.69M
Average 11.85M
MRK Total Liabilities
Everything the company owes to creditors and other parties.
Merck & Co., Inc.NYSE: MRK
Total Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total liabilities rises 28.3% from a year ago
Total liabilities stood at $87.82B at the end of Q2 FY2026, up 28.3% from a year earlier and up 6.1% from the prior quarter. Over 3 fiscal years it compounded at +10.1% a year.
Context
- Total liabilities amounted to 67.7% of total assets at the end of Q2 FY2026, up 9.4 pp from a year earlier.
- Total liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +28.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 84.2B USD
- Year-over-year change
- +19.0%
- 4-year CAGR
- +5.7%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 84.2B | +19.0% |
| FY2024 | 2024-12-31 | 70.73B | +2.5% |
| FY2023 | 2023-12-31 | 69.04B | +9.4% |
| FY2022 | 2022-12-31 | 63.1B | -6.4% |
| FY2021 | 2021-12-31 | 67.44B | — |
Total Liabilities vs competitors
How MRK compares with its peers on the latest reported figures
- Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +28.3% is the 3rd highest of 10, against a peer median of +4.1%.
- Total liabilities amounts to 67.7% of total assets for MRK, versus a peer median of 65.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $141B USD | +2.7% | +4.1% | 104.3% | |
| Sep 2026 | $115.9B USD | +2.1% | +2.1% | 58.7% | |
| Jun 2026 | $115.64B USD | -1.2% | +6.2% | 57.5% | |
| Jun 2026 | $108.4B USD | +31.3% | +30.4% | 76.2% | |
| Jun 2026 | $87.82B USD | +28.3% | +10.1% | 67.7% | |
| Jun 2026 | $83.95B USD | +4.3% | +10.1% | 87.8% | |
| Jun 2026 | $80.09B USD | +28.5% | +6.0% | 65.6% | |
| Sep 2026 | $67.99B USD | -0.7% | +3.2% | 56.8% | |
| Jun 2026 | €59.49B EUR | +8.8% | +2.2% | 46.1% | |
| Jun 2026 | $37.62B USD | +4.1% | -4.6% | 76.2% | |
| Peer median (excluding MRK) | — | +4.1% | +4.1% | 65.6% | |
Competitors are the stored peer set for MRK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 8.1B | 12.69B | 6.84B | 13.24B | 14.57B |
| Short-term Investments | 0 | 498M | 252M | 447M | 0 |
| Net Receivables | 9.23B | 9.45B | 10.35B | 10.28B | 12.68B |
| Inventory | 5.95B | 5.91B | 6.36B | 6.11B | 6.66B |
| Other Current Assets | 6.99B | 7.17B | 8.37B | 8.71B | 9.49B |
| Total Current Assets | 30.27B | 35.72B | 32.17B | 38.78B | 43.52B |
| Property, Plant & Equipment (Net) | 19.28B | 21.42B | 23.05B | 23.78B | 26.82B |
| Goodwill | 21.26B | 21.2B | 21.2B | 21.67B | 21.58B |
| Intangible Assets | 22.93B | 20.27B | 18.01B | 16.37B | 26.68B |
| Long-term Investments | 370M | 1.02B | 252M | 463M | 2.24B |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 11.58B | 9.53B | 12B | 16.04B | 16.03B |
| Total Non-current Assets | 75.43B | 73.44B | 74.51B | 78.32B | 93.35B |
| Total Assets | 105.69B | 109.16B | 106.68B | 117.11B | 136.87B |
| Account Payables | 4.61B | 4.26B | 3.92B | 4.08B | 4.4B |
| Short-term Debt | 2.41B | 1.95B | 1.37B | 2.65B | 2.88B |
| Tax Payables | 1.22B | 1.99B | 2.65B | 3.91B | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | (304M) | (281M) | (285M) | (282M) | 14.09B |
| Total Current Liabilities | 23.87B | 24.24B | 25.69B | 28.42B | 28.33B |
| Long-term Debt | 30.69B | 28.75B | 33.68B | 34.46B | 46.75B |
| Deferred Tax Liabilities | 3.44B | 1.8B | 871M | 1.39B | 1.44B |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 8.21B | 7.31B | 7.86B | 5.59B | 6.79B |
| Total Non-current Liabilities | 43.57B | 38.86B | 43.35B | 42.31B | 55.88B |
| Total Liabilities | 67.44B | 63.1B | 69.04B | 70.73B | 84.2B |
| Common Stock | 1.79B | 1.79B | 1.79B | 1.79B | 1.79B |
| Retained Earnings | 53.7B | 61.08B | 53.9B | 63.07B | 73.08B |
| Accumulated OCI | (4.43B) | (4.77B) | (5.16B) | (4.95B) | (4.29B) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 73M | 67M | 54M | 59M | 56M |
| Total Equity | 38.26B | 46.06B | 37.64B | 46.37B | 52.66B |
| Total Debt | 34.63B | 31.99B | 36.27B | 38.27B | 50.53B |
| Net Debt | 26.54B | 19.29B | 29.43B | 25.03B | 35.97B |
Merck & Co., Inc.
NYSE:MRK
Intrinsic Alpha fair value
Locked
Current Price
$137.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.